MedElevator
Войти в исследования The Journal of dermatological treatment · 2013
Topical nicotinamide for seborrheic dermatitis: an open randomized study.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fabbrocini Gabriella, Cantelli Mariateresa, Monfrecola Giuseppe
Аннотация
BACKGROUND: Treatment of seborrheic dermatitis (SD) includes various options with different success and safety limitations.
OBJECTIVE: To evaluate the efficacy of topical nicotinamide (NCT) in the treatment of SD.
METHODS: A total of 48 patients with mild to moderate SD of the face were enrolled in the study (36 males and 12 females; age 20-50 years). Patients were randomized into two groups A and B, who were treated once a day with topical administration of NCT 4% cream and with the vehicle without NCT (placebo), respectively. Clinical measures were assessed by erythema, scaling, and infiltration, which were evaluated using a four-point scale 0-3 before starting treatment and after 2, 6, and 12 weeks' therapy.
RESULTS: In comparison with baseline, a reduction of 75% of the total score was observed in patients treated with NCT, whereas for placebo-treated patients the reduction was of 35% (p < 0.05).
CONCLUSION: Topical NCT 4% can have a potential for the treatment of SD.
OBJECTIVE: To evaluate the efficacy of topical nicotinamide (NCT) in the treatment of SD.
METHODS: A total of 48 patients with mild to moderate SD of the face were enrolled in the study (36 males and 12 females; age 20-50 years). Patients were randomized into two groups A and B, who were treated once a day with topical administration of NCT 4% cream and with the vehicle without NCT (placebo), respectively. Clinical measures were assessed by erythema, scaling, and infiltration, which were evaluated using a four-point scale 0-3 before starting treatment and after 2, 6, and 12 weeks' therapy.
RESULTS: In comparison with baseline, a reduction of 75% of the total score was observed in patients treated with NCT, whereas for placebo-treated patients the reduction was of 35% (p < 0.05).
CONCLUSION: Topical NCT 4% can have a potential for the treatment of SD.